Risedronate Sodium

Osteoporosis, Malignant Neoplasms, Postmenopause + 3 more
Treatment
5 FDA approvals
20 Active Studies for Risedronate Sodium

What is Risedronate Sodium

Risedronic acidThe Generic name of this drug
Treatment SummaryRisedronic acid is a medication used to treat certain types of bone diseases such as osteoporosis and Paget’s disease. It works by blocking the breakdown of bone tissue, which helps keep bones strong and healthy.
Actonelis the brand name
image of different drug pills on a surface
Risedronate Sodium Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Actonel
Risedronic acid
1998
61

Approved as Treatment by the FDA

Risedronic acid, also called Actonel, is approved by the FDA for 5 uses including Therapeutic procedure and Paget’s Disease .
Therapeutic procedure
Paget’s Disease
Bone and Bones
Used to treat increased bone mass in combination with Calcium
Osteoporosis
Used to treat Osteoporosis in combination with Calcium
Postmenopause

Effectiveness

How Risedronate Sodium Affects PatientsRisedronate is a drug that helps prevent bone loss by stopping cells (osteoclasts) from breaking down the bones.
How Risedronate Sodium works in the bodyRisedronatic acid works to stop bone resorption. It binds to the surface of bones, and when the bone is broken down, risedronatic acid is released. The acid is taken up by nearby osteoclasts, which are cells that break down bone. It stops the osteoclasts from functioning, which prevents further bone breakdown.

When to interrupt dosage

The measure of Risedronate Sodium is contingent upon the acknowledged malady, including Therapeutic procedure, Malignant Neoplasms and Postmenopause. The quantity of dosage fluctuates as per the technique of delivery featured in the table beneath.
Condition
Dosage
Administration
Bone and Bones
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit
Osteoporosis
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit
Malignant Neoplasms
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit
Postmenopause
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit
Therapeutic procedure
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit
Paget’s Disease
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Kit; Tablet, Kit; Tablet - Oral, Kit

Warnings

Risedronate Sodium Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Risedronic Acid may interact with Pulse Frequency
Hypocalcemia
Do Not Combine
Postural Orthostatic Tachycardia Syndrome
Do Not Combine
There are 20 known major drug interactions with Risedronate Sodium.
Common Risedronate Sodium Drug Interactions
Drug Name
Risk Level
Description
Etidronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Etidronic acid.
Incadronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Incadronic acid.
Tiludronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Tiludronic acid.
Acipimox
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Acipimox.
Aluminium clofibrate
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Aluminium clofibrate.
Risedronate Sodium Toxicity & Overdose RiskOver 10% of patients taking this drug may experience back pain, joint pain, abdominal pain, and indigestion. Other rare side effects include swelling of the face, rashes, eye irritation, and inflammation of the eye.An overdose may cause decreased levels of calcium and phosphorus in the blood. Milk or antacids can be taken to reduce absorption of the drug. In more severe cases, doctors may recommend stomach pumping or intravenous calcium. In rats, a fatal dose was found to be 320 to 620 times the dose given to humans.
image of a doctor in a lab doing drug, clinical research

Risedronate Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Risedronate Sodium?

50 active studies are being conducted to explore the potential of Risedronate Sodium to alleviate Paget’s Disease, Postmenopausal symptoms and Malignant Neoplasms.
Condition
Clinical Trials
Trial Phases
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Therapeutic procedure
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting
Bone and Bones
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Risedronate Sodium Reviews: What are patients saying about Risedronate Sodium?

2Patient Review
12/31/2014
Risedronate Sodium for Osteoporosis
I've been taking this medication for a while now, but I'm starting to experience some serious pain in my legs. Additionally, I get bad indigestion and sometimes feel like I'm choking. Going to see the doctor soon.
2Patient Review
4/15/2014
Risedronate Sodium for Osteoporosis caused by Glucocorticoid Drugs
Two days after taking the first pill, one of my eyes was almost completely closed. Is this a big concern?
2Patient Review
6/14/2010
Risedronate Sodium for Osteoporosis
I would rather break my bones than use this again. The side effects were very painful.
1.7Patient Review
5/6/2008
Risedronate Sodium for Osteoporosis
I had to stop taking this medication as it caused stomach ulcers, despite me following all the directions. It also lowered my red blood count because of the bleeding.
1.7Patient Review
7/19/2017
Risedronate Sodium for Osteoporosis
I have a lot of pain in my muscles and joints. It's tough to be active when some days I can hardly move. Many mornings it hurts a lot just to get out of bed.
1Patient Review
1/13/2016
Risedronate Sodium for Osteoporosis
The side effects of this drug were so severe that I had to go to the hospital. They couldn't do anything but tell me it would take a week or two to get out of my system. Definitely not worth it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about risedronate sodium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long should you take risedronate sodium?

"You should take risedronate regularly to get the full benefits. Your doctor should review your treatment after five years to make sure the benefits of taking risedronate continue to outweigh any risks."

Answered by AI

Why do you have to stay upright after taking risedronate?

"Do not lie down for 30 minutes after taking risedronate. This will help risedronate reach your stomach faster. It also will help prevent irritation to your esophagus. It is important that you eat a well-balanced diet with adequate amounts of calcium and vitamin d to help prevent bone loss."

Answered by AI

What is risedronate sodium used for?

"This medication is used by adults to treat a disease that weakens bones (Paget's disease). This medication helps to reduce bone pain and may prevent long-term complications from this disease. Risedronate works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures)."

Answered by AI

What are side effects of risedronate?

"Having trouble with bowel movements, either constipation or diarrhea? experiencing indigestion, bloating, stomach pain or wind? You might also be feeling sick to your stomach (nausea), have headaches, or mild muscle, bone or joint pain."

Answered by AI

Clinical Trials for Risedronate Sodium

Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR
The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks
Recruiting
Has No Placebo
Don tyson Center for Agricultural Sciencers (+1 Sites)Jamie Baum
Have you considered Risedronate Sodium clinical trials? We made a collection of clinical trials featuring Risedronate Sodium, we think they might fit your search criteria.Go to Trials
Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD
Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.
Waitlist Available
Has No Placebo
University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)Denise Orwig, PhD
Image of Arthritis Research Canada in Vancouver, Canada.

Virtual Rehabilitation for Spinal Fracture

18+
All Sexes
Vancouver, Canada
Spine fractures are the most common fracture due to osteoporosis. They happen during falls or activities of daily life, like bending to tie shoes. Fractures of the spine can result in pain, which can sometimes last for a long time. Spine fractures can affect breathing, appetite, digestion, and mobility, and can restrict or modify people's work or daily activities. There are no standard rehabilitation programs after spine fracture, and patients often have to pay for rehabilitation. Rehabilitation can be hard to access, especially in rural or remote locations. It can be hard to find health care or rehabilitation providers who specialize in treating spine fractures. After reviewing research and consulting patients and health care providers to understand their experiences with spine fracture rehabilitation, the research team developed a toolkit for a virtual rehabilitation program for people with spine fractures, called VIVA. The research team wants to submit a grant for a clinical trial to implement VIVA in five provinces and determine if VIVA reduces pain and improves physical functioning and quality of life, and if the benefits outweigh the costs. Before this, the team proposes to do a pilot study to test how feasible it is to do a study of VIVA in three provinces.
Recruiting
Has No Placebo
Arthritis Research Canada (+5 Sites)Lora Giangregorio, PhD
Have you considered Risedronate Sodium clinical trials? We made a collection of clinical trials featuring Risedronate Sodium, we think they might fit your search criteria.Go to Trials
Image of Marcus Institute for Aging Research, Hebrew SeniorLife in Boston, United States.

Injury Prevention Care Models for Osteoporosis

65+
All Sexes
Boston, MA
The goal of this clinical trial is to compare three care models for optimizing medications and preventing falls with broken bones in patients receiving rehabilitation after a hospitalization for a broken bone. The primary outcome is injurious falls, with secondary outcomes measuring how the process of care is changed and capturing patient-reported outcomes valued by stakeholders. The main questions this study aims to answer are: * Which of the three models is more effective in preventing falls with fractures? * What are the differences in patient-centered outcomes amongst the three models? These include pain, depression, anxiety, sleep, medication side effect burden, and fear of falling. * What are the differences in osteoporosis treatment and medication burden? The three care models are: a Deprescribing Care Model designed to reduce or stop fall-related medications, a Bone Heath Service Model designed to provide osteoporosis evaluation and management, and an Injury Prevention Service Model offering both services. 42 SNFs will participate in this study. The three models will be incorporated into the routine care of patients at these facilities who are receiving rehabilitation after a hospitalization for a fracture. All care models will be delivered remotely to patients in the SNF and after they transition home by a post-fracture nurse consultant supported by an interprofessional team. This study has three aims. See Detailed Description for more details. This ClinicalTrials.gov record represents the Comparative Effectiveness Aim of the protocol.
Waitlist Available
Has No Placebo
Marcus Institute for Aging Research, Hebrew SeniorLife (+1 Sites)Cathleen S Colon-Emeric, MD, MHS
Image of University of Saskatchewan in Saskatoon, Canada.

Milk + Yogurt for Bone Health

19 - 30
All Sexes
Saskatoon, Canada
Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption.
Recruiting
Has No Placebo
University of SaskatchewanHassan Vatanparast, MD, PhD
Image of University of Kentucky in Lexington, United States.

Teriparatide vs Alendronate for Osteoporosis

18+
Female
Lexington, KY
Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality. Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem. Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment.
Phase 4
Waitlist Available
University of KentuckyPaul Netzel, DNP
Have you considered Risedronate Sodium clinical trials? We made a collection of clinical trials featuring Risedronate Sodium, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security